The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Objectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice. Methods. A total of 81 previously un...

Full description

Bibliographic Details
Main Authors: Yoshinori Tanaka, Yasushi Tanuma, Naoya Masumori
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:Advances in Urology
Online Access:http://dx.doi.org/10.1155/2017/4842025
id doaj-7e9a2549d5cc4bceac0bd53c81d623a9
record_format Article
spelling doaj-7e9a2549d5cc4bceac0bd53c81d623a92020-11-24T23:53:17ZengHindawi LimitedAdvances in Urology1687-63691687-63772017-01-01201710.1155/2017/48420254842025The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic HyperplasiaYoshinori Tanaka0Yasushi Tanuma1Naoya Masumori2Division of Urology, Hokkaido Prefectural Esashi Hospital, Esashi, JapanDivision of Urology, Hokkaido Social Welfare Association Hakodate Hospital, Hakodate, JapanDepartment of Urology, Sapporo Medical University School of Medicine, Sapporo, JapanObjectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice. Methods. A total of 81 previously untreated Japanese patients diagnosed with LUTS/BPH were treated with silodosin monotherapy and prospectively followed for 4 years. The persistence rate was estimated using the Kaplan-Meier method. If silodosin had to be terminated or a patient did not come to the hospital, the reason was determined. Results. The 6-month, 1-year, 2-year, 3-year, and 4-year persistence rates were 63.0%, 56.8%, 50.6%, 44.4%, and 35.8%, respectively. The most frequent reason (22.2%) for withdrawal was symptom resolution. After silodosin treatment, the international prostate symptom score and the quality of life index were significantly improved and maintained for 4 years. Conclusions. 35.8% of previously untreated Japanese patients continued silodosin for 4 years. Many patients terminated silodosin for various reasons, the most frequent of which was symptom resolution. The effects of silodosin were maintained when the patients continued treatment. Trial Registration. This study was approved by the institutional review board of Hokkaido Prefectural Esashi Hospital (number 2007-2) and was registered in a public trial registry (UMIN000026910).http://dx.doi.org/10.1155/2017/4842025
collection DOAJ
language English
format Article
sources DOAJ
author Yoshinori Tanaka
Yasushi Tanuma
Naoya Masumori
spellingShingle Yoshinori Tanaka
Yasushi Tanuma
Naoya Masumori
The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
Advances in Urology
author_facet Yoshinori Tanaka
Yasushi Tanuma
Naoya Masumori
author_sort Yoshinori Tanaka
title The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
title_short The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
title_full The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
title_fullStr The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
title_full_unstemmed The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
title_sort persistence of silodosin monotherapy and the reasons for withdrawal from treatment of previously untreated japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
publisher Hindawi Limited
series Advances in Urology
issn 1687-6369
1687-6377
publishDate 2017-01-01
description Objectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice. Methods. A total of 81 previously untreated Japanese patients diagnosed with LUTS/BPH were treated with silodosin monotherapy and prospectively followed for 4 years. The persistence rate was estimated using the Kaplan-Meier method. If silodosin had to be terminated or a patient did not come to the hospital, the reason was determined. Results. The 6-month, 1-year, 2-year, 3-year, and 4-year persistence rates were 63.0%, 56.8%, 50.6%, 44.4%, and 35.8%, respectively. The most frequent reason (22.2%) for withdrawal was symptom resolution. After silodosin treatment, the international prostate symptom score and the quality of life index were significantly improved and maintained for 4 years. Conclusions. 35.8% of previously untreated Japanese patients continued silodosin for 4 years. Many patients terminated silodosin for various reasons, the most frequent of which was symptom resolution. The effects of silodosin were maintained when the patients continued treatment. Trial Registration. This study was approved by the institutional review board of Hokkaido Prefectural Esashi Hospital (number 2007-2) and was registered in a public trial registry (UMIN000026910).
url http://dx.doi.org/10.1155/2017/4842025
work_keys_str_mv AT yoshinoritanaka thepersistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia
AT yasushitanuma thepersistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia
AT naoyamasumori thepersistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia
AT yoshinoritanaka persistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia
AT yasushitanuma persistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia
AT naoyamasumori persistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia
_version_ 1725470591955238912